Skip to main content
Premium Trial:

Request an Annual Quote

Cellectis Plant Sciences Inks CRISPR/Cas9 Licensing Deal with U of Minnesota

NEW YORK (GenomeWeb) – Cellectis Plant Sciences today announced it has signed an exclusive licensing agreement with the University of Minnesota, granting the firm worldwide rights to patents covering the use of CRISPR/Cas9 technology in plants.

The technology, developed for genome engineering in plants by University of Minnesota Professor Dan Voytas, strengthens Cellectis' gene editing property rights, the firm said in a statement. Cellectis also has rights to use meganuclease and transcription activator-like effector nuclease-based gene editing technologies.

Applying CRISPR/Cas9 gene editing in plants could help scientists develop valuable crops, the firm said in a statement.

Financial and other details of the agreement were not disclosed.